Insights › Likitanci da magunguna › November 13, 2026
Likitanci da magunguna · Bayanan hukuma

EMA ta amince da Ruxolitinib Krka don cutar myelofibrosis da polycythaemia vera

European Union EMA (New human medicines) An wallafa:

Kwamitin EMA na Kayan Magani don Amfani da Mutane ya amince da kyakkyawan ra'ayi a ranar 12 ga Nuwamba, 2026, yana ba da shawarar izinin tallace-tallace don Ruxolitinib Krka. Wannan magani na gama-gari daga KRKA an tsara shi ne don magance cutar myelofibrosis da polycythaemia vera, wanda ke fadada zabin magani a EU.

Asalin tushe
Karanta tushen — ema.europa.eu ↗

Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.

Ƙari a Likitanci da magunguna

Duba komai a cikin Likitanci da magunguna →

Ƙara bincika wannan batu

Karanta kowane bayani da yarenka

Wannan shafi yana nuna sabbin abubuwa uku ne kawai a kowane fanni. Mambobi na ganin kowane bayani a cikin fannin, a harsuna 109, tare da injinan bincike da ke aiki a kansu.

Karanta duka — fara daga $3Babu buƙatar shigarwa daga kantin manhajoji. Ana iya soke shi kowane lokaci.